Skip to main content
Clinical Trials/NCT00746135
NCT00746135
Completed
Not Applicable

TRI-V Resynchronization in Paced Heart Failure Patients With ICD Indication.

Abbott Medical Devices1 site in 1 country40 target enrollmentNovember 2007
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Abbott Medical Devices
Enrollment
40
Locations
1
Primary Endpoint
Improvement according to Packer's "Heart Failure Clinical Composite Respond"
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

It's the aim of this study to investigate the impact of Right Ventricular (RV) lead position (RV-apex, His bundle area, RV-apex+His bundle area) in combination with individually optimized Left Ventricular (LV) lead placement and CRT timing on the outcome of cardiac resynchronization therapy (CRT).

Registry
clinicaltrials.gov
Start Date
November 2007
End Date
December 2012
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with indication for CRT-D: NYHA III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure
  • LVEDD \> 55 mm or \> 30 mm/m² BSA
  • EF \< 35%
  • Sinus rhythm and one of the following criteria:
  • QRS \>= 120 ms and PQ \>= 200ms
  • 2nd / 3rd degree AV block
  • Written informed consent

Exclusion Criteria

  • pacemaker indication (without ICD indication)
  • tricuspidal valve and/or aortic valve replacement
  • Indication for revascularization.
  • less than 3 month after heart surgery or myocardial infarction
  • hypertrophic obstructive cardiomyopathy
  • intravenous catecholamine treatment
  • uncorrected thyroid function
  • severe kidney disorder (creatinin \>2,5mg%)
  • no written patient consent
  • insufficient patient compliance

Outcomes

Primary Outcomes

Improvement according to Packer's "Heart Failure Clinical Composite Respond"

Time Frame: 12 months post implant

Secondary Outcomes

  • Change in B-type natriuretic Peptide (BNP)-Concentration(12 months)
  • 6 min walk test(12 months)
  • Intraoperative Increase in Left Ventricular dp/dt(At Implant)
  • QoL assessment("Minnesota Living with Heart Failure = MLHF)(12 months)
  • Cardiopulmonary Capacity(Spiroergometry)(12 months)
  • 2D-echo optimized EF(12 months)
  • 12 channel ECG(12 months)
  • Complications and morbidity(12 months)

Study Sites (1)

Loading locations...

Similar Trials